H.C. Wainwright lowered the firm’s price target on Legend Biotech (LEGN) to $60 from $75 and keeps a Buy rating on the shares. Johnson & Johnson (JNJ) reported a Q3 sales beat for Carvykti but Legend Biotech shares had a muted reaction, the analyst tells investors in a research note. The firm believes this reflects Carvykti growth already being priced into the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s CARVYKTI® Receives FDA Approval for Label Update with New Survival Data
- Legend Biotech Reports Strong CARVYKTI® Sales for Q3 2025
- Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings Release as Cancer Therapy Gets Warning Label
- Legend Biotech and Janssen Forge Strategic Supply Agreement
- Legend Biotech’s Strategic Positioning and Growth Potential: Overcoming Supply Constraints and Sustaining Leadership in the BCMA CAR T Space